trending Market Intelligence /marketintelligence/en/news-insights/trending/9H0C_OVTBOJIRKxu72LCdw2 content esgSubNav
In This List

Organovo expands board with addition of new director

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Organovo expands board with addition of new director

Organovo Holdings Inc. appointed David Shapiro as a director, increasing the size of its board to eight members.

Shapiro has served as the chief medical officer of Intercept Pharmaceuticals Inc. since November 2017.

Organovo is a biotech platform company providing 3D bioprint tissues with human functionality.